Point72 Asset Management
PPBT

Point72 Asset Management’s Purple Biotech PPBT Stock Holding History

Point72 Asset Management’s Portfolio PPBT Stock Details PPBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,357
Closed -$1.07M – 1588
2022
Q1 		$1.07M Sell
1,357
-39
-3% -$25.2K ﹤0.01% 948
2021
Q4 		$1.09M Hold
1,396
– – ﹤0.01% 900
2021
Q3 		$1.28M Sell
1,396
-1,229
-47% -$1.19M 0.01% 833
2021
Q2 		$2.56M Buy
+2,625
New +$2.41M 0.01% 704

Other funds holding PPBT

Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WTB
Washington Trust Bank Spokane, Washington $1.36B AUM 21.14% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
VVP
Venture Visionary Partners Sylvania, Ohio $3.6B AUM 30.03% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Point72 Asset Management's PPBT Position: Q2 2022 in Review

Point72 Asset Management sold out of Purple Biotech (PPBT) in Q2 2022, closing a stake of 1,357 shares — an estimated $1.07M sold.

Point72 Asset Management first reported a position in PPBT in Q2 2021 and held it in 4 quarters. The position peaked at $2.56M in Q2 2021. 12 funds tracked by Wall St. Rank hold PPBT as of Q2 2022.

  • Point72 Asset Management reported no remaining Purple Biotech position as of Q2 2022 after selling out during the quarter.
  • Point72 Asset Management sold 1,357 Purple Biotech shares in Q2 2022, an estimated $1.07M.
  • Point72 Asset Management first reported a position in Purple Biotech in Q2 2021 and held it in 4 quarters.
  • Point72 Asset Management's Purple Biotech position peaked at $2.56M in Q2 2021.
  • 12 funds tracked by Wall St. Rank held Purple Biotech as of Q2 2022.

Based on Point72 Asset Management's 13F filing for Q2 2022, filed 15 Aug 2022.